Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743446 | 0.85 | HDAC8 (0.45) | CYP4A11CYP4F2CA2KDM4EF13A1 | |
| SCHEMBL9199658 | 0.80 | CES2 (0.39) | KDM4EF13A1TSHR | |
| SCHEMBL6670487 | 0.75 | ALDH1A1 (0.48) | KDM4E | |
| SCHEMBL60234 | 0.72 | AKR1C3 (0.48) | TDP1TSHR | |
| SCHEMBL8868410 | 0.72 | KMT2A (0.61) | CYP4A11CYP4F2ACACBCA2KDM4E | |
| SCHEMBL6629816 | 0.72 | SMN1; SMN2 (0.57) | CYP4A11CYP4F2TDP1CA2KDM4E | |
| SCHEMBL1410852 | 0.71 | AKR1C3 (0.58) | CYP4A11CYP4F2TDP1CA2PPARA | |
| SCHEMBL1410851 | 0.71 | AKR1C3 (0.58) | CYP4A11CYP4F2TDP1CA2PPARA | |
| Phenylethyl Alcohol SCHEMBL183529 | 0.70 | TDP1 (0.76) | CYP4A11CYP4F2TDP1CA2PPARA | |
| SCHEMBL77237 | 0.70 | CA2 (0.52) | CYP4A11CYP4F2TDP1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024071320-A1 | COMPOUND PRODUCTION METHOD | 国立大学法人東京大学 | 2024-04-04 | — | — | WO | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| EP-3988170-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3157571-B1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| EP-3887388-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3851445-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | Novartis AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20210138037-A1 | NOVEL APPLICATION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FOR MEDICAL PURPOSES | KAGOSHIMA UNIVERSITY (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10905742-B2 | Application of heparin-binding epidermal growth factor-like growth factor for medical purposes | KAGOSHIMA UNIVERSITY (JP) | 2021-02-02 | — | — | US | disclosed |
| EP-0873998-A2 | Receptor protein and its use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998046767-A1 | PROTEINS HAVING LECITHIN-CHOLESTEROL ACYLTRANSFERASE-LIKE ACTIVITY, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| EP-0870020-A2 | LIGAND POLYPEPTIDES FOR THE G-PROTEIN-COUPLED RECEPTOR PROTEIN, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0856582-A2 | Inhibitor protein of transcription factors and its DNA | Takeda Chemical Industries, Ltd. (JP) | 1998-08-05 | — | — | EP | disclosed |
| WO-1998011130-A2 | MAMMALIAN EPENDYMIN-LIKE PROTEINS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-19 | — | — | WO | disclosed |
| EP-0824149-A2 | Glutamine: fructose-6-phosphate amidotransferase (GFAT), its production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-02-18 | — | — | EP | disclosed |
| WO-1998003648-A1 | FAS LIGAND-LIKE PROTEIN, ITS PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997040157-A1 | MATRIX METALLOPROTEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| EP-0799892-A2 | Calpain, its production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997024436-A2 | LIGAND POLYPEPTIDES FOR THE G-PROTEIN-COUPLED RECEPTOR PROTEIN, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | CYP4A11 1517/4885CYP4F2 788/4885ACACB 183/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | CYP4A11 1601/4885CYP4F2 745/4885ACACB 174/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | CYP4A11 185/4885CYP4F2 2857/4885ACACB 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.